The rise of fentanyl and other synthetic opioids is unlike any drug crisis in U.S. history. Limiting policy responses to existing approaches will likely be insufficient and may condemn many people to early deaths.
We review the change over time in state-level policy environments around substance use in pregnancy and contrast the policy response with the principles and guidance from professional societies and federal agencies.
A study examined the rates of hospitalisation or death related to severe bacteria infections among people who inject heroin in South London, England. The report compared these rates to the general population and calculated the cost of admissions.
Driving under the influence of drugs is a serious and growing threat to public safety. Addressing these cases involves identifying impairment and presenting complex evidence in court. A panel of experts identified ways to address this challenge.
This study found an increase in the rate of overdose after Medicare Part D coverage began to include benzodiazepines among adults aged 65 to 69 years and 80 years or older and an increase in the rate of fall-related injury in adults 80 years or older.
In the profitable buprenorphine market, pharmaceutical manufacturer Reckitt Benckiser exploited various Food and Drug Administration regulatory procedures to impede entry of generic competitors and maintain elevated prices.
State-level prescription drug monitoring programs that incorporate robust design features can significantly reduce the proportion of commercially insured adults who receive opioid prescriptions as well as the strength of those prescriptions.
Early evidence suggests that opioid duration limits had a variable association with postoperative opioid prescribing and should only be part of a larger, multifaceted effort to reduce excessive postoperative opioid prescribing.
In this article, the authors use the case of Suboxone to demonstrate egregious anti-competitive practices that delay generic entry, estimate the costs of these delays to the public, and suggest legislative and regulatory reforms to prevent these practices going forward.
Policymakers can wield a multitude of tools to address vaping-related illness. Cannabis policy reform is one option. But policymakers may face challenges in balancing comprehensive regulatory design that promotes product safety with its potential to bolster the illegal and unregulated market.
Few people foresaw how quickly fentanyl would displace heroin, doubling or tripling opioid overdose deaths in some pockets of the United States from 2013 to 2017. But we could have been warned—if only we'd checked our wastewater.